Want to join the conversation?
Morgan Stanley analyst Matthew Granger asks $K how improving mix & revenue management will bridge the gap to get to 18% target of expense savings. $K says that looking to 2017-2018, it has cost savings of between $130-150MM. $K is putting effort behind revenue growth management to generate stronger price & mix to achieve the margin expansion goal.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?